Actively Recruiting
A Prospective Study on Tissue-resident Immune Cell Subsets and Acute Graft-versus-Host Disease Following Hematopoietic Stem Cell Transplantation
Led by Nanfang Hospital, Southern Medical University · Updated on 2024-11-27
40
Participants Needed
1
Research Sites
15 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating how different tissue-resident immune cell types relate to the development and progression of acute graft-versus-host disease (aGVHD) following hematopoietic stem cell transplantation. This prospective, observational study aims to understand these immune cells' role by following patients with varying severity of aGVHD. Approximately 40 participants will be enrolled, including 20 patients with severe (grade 3-4) aGVHD and 20 with milder (grade 1-2) aGVHD. The study does not provide any treatments or randomize participants; instead, patients will continue to receive usual care as determined by their doctors. Participants will be followed monthly over about three months, from November 2024 to February 2025. During this time, researchers will observe and collect data related to immune cell subsets in organs and their association with aGVHD severity and patient outcomes. Participants will be monitored regularly to assess acute graft-versus-host disease status, overall survival, and disease-free survival during the 100-day follow-up. Data collection will include grading aGVHD according to established guidelines. The study focuses on understanding immune cell behavior without altering treatment, allowing researchers to observe natural disease progression and outcomes in real-world care settings.
CONDITIONS
Brief Title
Tissue-resident Immune Cell Subsets in aGVHD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntarily sign the informed consent form
- Age between 16 and 65 years
- Clinically diagnosed with graft-versus-host disease for the first time or currently receiving graft-versus-host disease treatment
You will not qualify if you...
- History of other tumors
- Poor compliance or mental disorders
- Infection with HIV or hepatitis C virus
- Uncontrolled hepatitis B infection
- Presence of other autoimmune diseases
- Judged by the researcher to be unsuitable to participate in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 3 months
Participants who have undergone hematopoietic stem cell transplantation and are diagnosed with acute graft-versus-host disease are observed without protocol-driven treatments. Their tissue-resident immune cell subsets and clinical outcomes are monitored.
Monthly visits for 3 months
Trial Site Locations
Total: 1 location
1
Nanfang Hospital, Southern Medical University
Guangzhou, Other (Non U.s.), China, 510000
Actively Recruiting
Research Team
Y
Yiming Sun
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here